Shares of Veracyte Inc. (VCYT) surged 8.5% in premarket trading on Tuesday, fueled by the company's impressive third-quarter 2024 financial results and bullish analyst reactions.
Veracyte reported quarterly adjusted earnings of $0.19 per share, significantly higher than analysts' expectations of $0.03 per share. The company's revenue also exceeded estimates, rising 28.6% year-over-year to $115.86 million, surpassing the consensus forecast of $109.81 million.
Following the strong quarterly performance, several analysts have raised their price targets and reiterated buy ratings on Veracyte. UBS analyst raised the firm's price target on Veracyte to $46 from $43, citing the company's robust financial results and growth potential. Needham analyst Michael Matson reiterated a Buy rating and increased the price target to $44, highlighting Veracyte's strong financial performance and growth prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。